HFA Premium Access

Combination treatment by epoxyeicosatrienoic acid analog and angiotensin-convertase enzyme inhibitor in congestive heart failure: a preclinical study on animal model

Congress Presentation

About the speaker

Doctor Petr Kala

Motol University Hospital, Prague (Czechia)
0 follower

38 more presentations in this session

Empagliflozin improves cardiovascular and renal outcomes in patients with preserved ejection fraction irrespective of age: insights from the EMPEROR-Preserved trial

Speaker: Professor M. Boehm (Homburg, DE)

Thumbnail

Novel kidney injury markers (NGAL and KIM-1) and outcomes in patients with heart failure- Systematic review and meta-analysis

Speaker: Doctor A. Kumar (Little Rock, US)

Thumbnail

Right ventricular dilatation as a manifestation of right ventricular dysfunction in patients with HFrEF: a new concept of evaluation

Speaker: Doctor J. Benes (Prague, CZ)

Thumbnail

Long-term prognostic implications of in-hospital changes in N-terminal pro-B-type natriuretic peptide levels among hospitalized patients with atrial fibrillation with or without heart failure

Speaker: Mr A. Samaras (Thessaloniki, GR)

Thumbnail

Perirenal adipose tissue is associated with renal dysfunction in patients with heart failure and preserved ejection fraction

Speaker: Ms E. Boorsma (Groningen, NL)

Thumbnail

Access the full session

Heart Failure ePosters - focus on Chronic Heart Failure 1

Speakers: Doctor P. Kala, Professor M. Boehm, Doctor A. Kumar, Doctor J. Benes, Mr A. Samaras...
Thumbnail

About the event

Image

Heart Failure 2022

21 May - 24 May 2022

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb